ECOR1 CAPITAL, LLC

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/28/2024

Adviser Type:

- Large advisory firm

Number of Employees:

21 23.53%

of those in investment advisory functions:

8 14.29%

Registration:

SEC, Approved, 7/2/2015

Other registrations (2)
AUM:

5,001,741,440 6.15%

of that, discretionary:

5,001,741,440 6.15%

GAV:

5,001,741,441 6.15%

Avg Account Size:

1,000,348,288 6.15%

SMA’s:

NO

Private Funds:

3

Contact Info

415 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
5B 4B 3B 3B 2B 1B 673M
2015 2016 2017 2018 2019 2020 2021 2022 2023

Recent News

Hedge Fund and Insider Trading News: Boaz Weinstein, Ken Griffin, EcoR1 Capital, Tiger Global Management, Odey Asset Management, Asana, Inc. (ASAN), and More
07/31/2023

EcoR1 Goes Bottom-Fishing (Institutional Investor) The biopharma and life sciences hedge fund firm is betting big on companies whose stocks have plummeted after reporting bad news. In recent weeks, EcoR1 Capital has sharply boosted its stake in at least four of its major holdings and established a sizable new position in another company, according to […]

Insider Monkey

EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc
07/28/2023

Related Stocks: MRSN, GLPG, PRTA, SRPT, ANAB, APLS,

gurufocus.com

EcoR1 Capital, LLC Increases Stake in Apellis Pharmaceuticals Inc
07/19/2023

Check out Vanguard Health Care Fund Stock Picks » Download GuruFolio Report of Vanguard Health Care Fund (Updated on 07/17/2023), Check out Jefferies Group Stock Picks » Download GuruFolio Report of Jefferies Group (Updated on 07/17/2023), Check out Joel Gre Stock Picks » Download GuruFolio Report of Joel Gre (Updated on 07/17/2023)Related Stocks: APLS, GLPG, PRTA, SRPT,...

gurufocus.com

EcoR1 Capital, LLC Buys Galapagos NV, Arcus Biosciences Inc, Protagonist Therapeutics Inc, ...
11/15/2021

Related Stocks: RCUS, GRTS, RNA, NRIX, DSGN, ODT, GLPG, PTGX, TNGX, ERAS, IMVT, BLUE, TBIO, KYMR, ARVN, BCEL, KDNY, ZNTL,

gurufocus.com

Savara Inc.
04/06/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

Dollar Keeps Citigroup, Morgan Stanley Wary of Emerging Markets
04/05/2021

(Bloomberg) -- Emerging-market investors reeling from last month’s losses head into the first full week of April bracing for more pain driven by higher U.S. Treasury yields and a stronger dollar. Stronger-than-expected U.S. jobs data on Friday prompted ...

Yahoo Finance


Private Funds Structure

Fund Type Count GAV
Hedge Fund 2 $4,916,469,779
Venture Capital Fund 1 $85,271,662

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
SAGE MOUNTAIN ADVISORS, LLC 25.4m - - - - 6.3m - 38.0m 2.2b 3
MIG CAPITAL, LLC 1.2b - - - - - - 1.2b 1.2b 2
GLOBAL FRONTIER INVESTMENTS, LLC 38.5m - - - - 56.2m - 150.9m 398.2m 3
LIVIAN & CO., LLC 3.6m - - - - 1.1m - 5.7m 123.5m 3
CORAL CAPITAL MANAGEMENT LLC 43.9m - - - - 17.2m - 78.2m - 4
ZILKHA INVESTMENTS, L.P. 65.6m - - - - 2.5m - 70.6m - 3
PANTERA ADVISORS LLC 2.5b - - - - 1.8b - 6.2b 4.2b 12
MIO PARTNERS, INC. 20.1b - - - - 30.7m - 20.2b 47.8b 14
ARCA INVESTMENT MANAGEMENT, LLC 199.2m - - - - 91.5m - 382.2m 193.8m 6
ARS INVESTMENT PARTNERS, LLC 13.8m - - - - 7.1m - 27.9m 1.6b 4

Private Funds



Employees




Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
03753U106 APELLIS PHARMACEUTICALS INC $668,819,850 17.00% 61.00% 3.00%
60468T105 MIRATI THERAPEUTICS INC $434,572,516 11.00% 74.00% 29.00%
G72800108 PROTHENA CORP PLC $420,972,735 11.00% -25.00% 0.00%
04335A105 ARVINAS INC $276,862,370 7.00% 158.00% 23.00%
36315X101 GALAPAGOS NV $233,992,294 6.00% 18.00% 0.00%
004225108 ACADIA PHARMACEUTICALS INC $187,593,207 5.00% 50.00% 0.00%
032724106 ANAPTYSBIO INC $161,100,334 4.00% 19.00% 0.00%
98985Y108 ZYMEWORKS INC $139,615,344 4.00% 64.00% 0.00%
98401F105 XENCOR INC $112,147,815 3.00% 5.00% 0.00%
87583X109 TANGO THERAPEUTICS INC $131,974,286 3.00% 34.00% 53.00%

Brochure Summary

Overview

EcoR1 Capital, LLC (“EcoR1”) is a limited liability company that has been in business since 2012. EcoR1’s manager, controlling owner and portfolio manager is Oleg Nodelman. As of December 31, 2022, EcoR1 had total discretionary net assets under management of approximately $4.712 billion. EcoR1 only manages assets on a discretionary basis. EcoR1 serves as the general partner of and investment adviser to the EcoR1 Capital Funds (the “Capital Funds”), which invest principally, but not solely, in equity and equity-related securities that are issued by biotechnology companies and traded publicly in U.S. and non-U.S. markets. The Capital Funds also invest in illiquid securities (generally, restricted securities of public and private companies). EcoR1 also serves as the investment adviser to the EcoR1 Venture Opportunity Funds (the “Venture Funds”), which invest principally, but not solely, in restricted equity and equity-related securities issued by privately-held biotechnology companies globally. EcoR1 intends to allocate investment opportunities in such restricted securities between the Capital Funds and the Venture Funds as described in each fund’s offering materials. In the future, EcoR1 may, but is not required
to, offer one or more investors in its funds or clients (or any other persons) the right to participate in investments in which the Capital Funds or the Venture Funds participate if (a) EcoR1 believes that such participation would benefit those funds or the portfolio company or (b) EcoR1 determines that those funds have been allocated the full amount of such investment in the portfolio company in light of their risk-return profiles, available capital and other considerations EcoR1 determines to be relevant. Any such fund that may be established in the future is called an “SPV” and collectively, the “SPVs.” The Capital Funds, the Venture Funds and the SPVs are collectively referred to herein as “clients” or “funds.” EcoR1 selects all fund investments and strategies. While the offering documents for each fund describes the specific investment strategy that EcoR1 intends to follow for that fund, EcoR1 is generally authorized to enter into any type of investment transaction that it deems appropriate under the terms of the applicable fund’s or client account’s governing documents. The investors in the funds that EcoR1 manages have no opportunity to select or evaluate any fund investments or strategies. EcoR1 does not participate in wrap fee programs.